HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

archazolid A

inhibits vacuolar-type ATPase; isolated from Archangium gephyra; structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Müller, Rolf: 2 articles (01/2018 - 11/2017)
2.	Bischoff, Iris: 1 article (01/2018)
3.	Bräutigam, Jacqueline: 1 article (01/2018)
4.	Fürst, Robert: 1 article (01/2018)
5.	Luong, Betty: 1 article (01/2018)
6.	Menche, Dirk: 1 article (01/2018)
7.	Schwenk, Rebecca: 1 article (01/2018)
8.	Ardelt, Maximilian A: 1 article (11/2017)
9.	Lamb, Don C: 1 article (11/2017)
10.	Merk, Henriette: 1 article (11/2017)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Here, we used the well-established v-ATPase inhibitor archazolid, a natural product first isolated from the myxobacterium Archangium gephyra, to study the consequences of v-ATPase inhibition in endothelial cells (ECs), in particular on the interaction between ECs and cancer cells, which has been neglected so far. "
2.	Tics (Tic) 11/01/2017 - "Archazolid A is suggested as a promising therapeutic agent to block EMT and the generation of TICs. " 11/01/2017 - "Genetic knockdown and pharmacologic inhibition of the V-ATPase by Archazolid A interfere with the EMT process and inhibit TIC generation, as shown by a reduced formation of mammospheres and decreased cell motility. "

Related Drugs and Biologics

1.	Adenosine Triphosphatases (ATPase)